Medibio Limited (ASX: MEB) is a mental health technology company. MEB pioneers the utilization of circadian biometrics, as a method to enhance objective screening and diagnosing and managing mental health conditions.
In its recently released investors presentation, the company mentioned that its RE-STARTUP is progressing on plan which is as follows: Restructuring of the company’s Board and Key Management, New Cost Controlling method to cause Reduction in Cash Burn and Strengthening of the Regulatory Path, Prioritisation of Business Segments, Commercial launch of its corporate health product ilumenTM and Enhancement of Communication with Stakeholders. [optin-monster-shortcode id=”swikrbu1d9j9aq0o4cko”]
By the end of the trading session, on 27 March 2019, the stock of the company stood at a price of A$0.018, up by 20% from its previous close. Its market capitalization is around A$3.73 million with 248.8 million shares outstanding. The stock has generated a negative return of 77.40% in the last six months, and the YTD return also stands negative at 28.57%.
G Medical Innovations Holdings Limited
G Medical Innovations Holdings Limited (ASX: GMV) is a mobile health company for gen-next. The company has been developing and marketing clinical and customer medical-grade health monitoring solutions. It also provides with end-to-end support for projects related to e-health.
Recently, the company has notified the market that an extraordinary general meeting of Shareholders of GMV, would be held at the offices of Otsana Capital, 108 Outram Street, West Perth, Western Australia 6005 on Wednesday 24 April 2019, at 10.00am (AWST).
In its quarterly report ending 31 December 2018, the company recorded the net cash used in operating activities standing at US$2,708, 000. The net cash used in investing activities stood at US$1,959,000. The Cash and cash equivalents at the end of the quarter were recorded at US$2,634,000.
By the end of the trading session, on 27 March 2019, the stock of the company stood at a price of A$0.285, down by 1.724% from its previous close. Its market capitalization is around A$105.13 million with 362.5 million shares outstanding. The stock has generated a negative return of 17.14% in the last six months. However, it has offered a YTD return of 5.45% to its investors till date.
SomnoMed Limited (ASX: SOM) is known as the leader of oral appliance for the treatment of sleep apnea across the globe. The company has a passion for offering solutions related to sleep, leading towards healthy patients.
Recently, the company notified the market that a Texas-based customer of SomnoMed North America, namely Simple Sleep Services, LLC (S3) has shut down, effective 15 March 2019, post 6 years of its operation. During the time of closing its business, S3 owed US$805,000 to SomnoMed.
As per the legal advice, SomnoMed had received, it is being believed that there was a reasonable likelihood, that it might not recover the US$400,000 to US$805,000 amount. The non-receipt of the amount would have a direct influence on SomnoMed’s core business earnings in the second half of the FY2019. Also, the guidance of EBITDA for the core business of $5 to $5.5 million would have an impact by the above-mentioned amount.
In its half-year results ending 31 December 2018, the company recorded its Core revenues to be +15% from the previous year. The underlying EBITDA stood at $1.6m and +60% from the previous year.
By the end of the trading session, on 27 March 2019, the stock of the company stood at a price of A$1.760, down by 1.676% from its previous close. Its market capitalization is around A$112.42 million with 62.8 million shares outstanding. The stock has generated a negative return of 44.06% in the last year. However, in the previous 3 months, it has given a yield of 2.29%.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.